FDA Advisers Often Tied to Drug Industry Groups
A study finds patient and consumer representatives on FDA advisory committees frequently have ties to pharmaceutical industry-funded advocacy organizations.
Updated on Nov. 4, 2026 in Nutrition
Live Poll
Do you trust federal regulators to keep drug approval panels free of drugmaker influence?
Nearly 38 percent of FDA advisory committee meetings from 2013 to 2022 included a patient or consumer representative with active ties to a pharmaceutical industry-funded advocacy organization. The study was published online Oct. 7, 2026, in Health Affairs Scholar.
Why it matters
Patient and consumer representatives are meant to bring public perspectives into FDA drug reviews, so industry funding ties raise questions about how independent those voices are. The findings add to scrutiny of conflicts of interest in the advisory process that shapes which medicines reach the U.S. market.
The analysis covered FDA advisory committee meetings from 2013 to 2022 and found that for several committees the share of meetings with such ties exceeded 50 percent. Whether these affiliations affected committee decisions was not addressed in the findings.
The players
Genevieve Kanter
Genevieve Kanter is a researcher at the University of Southern California who led the study examining industry funding ties among patient and consumer representatives on FDA advisory committees.
University of Southern California
The University of Southern California is a private research university in Los Angeles whose researchers conducted the analysis.
Health Affairs Scholar
Health Affairs Scholar is an academic journal published by Oxford University Press that carries peer-reviewed research on health policy and health services.
The details
Researchers led by Genevieve Kanter of the University of Southern California examined how often patient and consumer representatives were actively involved with advocacy groups receiving pharmaceutical industry funding in the year they attended FDA meetings. The analysis also flagged 11 percent of meetings that included a representative tied to an organization funded by the sponsor of the drug being reviewed.
Timeline
2013-2022: Period of FDA advisory committee meetings analyzed in the study.
Oct. 7, 2026: Study published online in Health Affairs Scholar.
Big Picture
The study tests whether current FDA conflict-of-interest rules under the Federal Advisory Committee Act reach indirect industry ties through patient advocacy groups. Its findings suggest disclosure requirements may not capture affiliations that run through third-party organizations.
Patients who rely on FDA-approved medicines may want to know whether the advisory voices shaping approvals have financial ties to industry. Readers can check disclosure statements that accompany public FDA advisory committee meetings.
The takeaway
Transparency about who speaks for patients in FDA reviews matters for public trust in drug approvals. Watching disclosure records for advisory committee members can help readers judge whose perspective informs a medicine's review.
Further reading
Explore more on this topic in our Nutrition coverage.
Source note: This article includes information reported by Renal and Urology News.
Live Poll
Do you trust federal regulators to keep drug approval panels free of drugmaker influence?
